RxDoctor Payments Data

Monica Szalajko

Optometrist · Kingsport, TNNPI 1720436892

Payments from drug & device makers

$1,114in general payments, 2019–2025

Across 29 payments — averaging $38.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$310
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$251
  • Coopervision Inc.$134
  • Bausch & Lomb Americas Inc.$127
  • Aerie Pharmaceuticals, Inc.$77
  • Sun Pharmaceutical Industries Inc.$54
  • plus $162 from 6 others

What the payments were for

  • Speaking & faculty fees$262%
  • Food & beverage$1,08998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,114 in reported general payments places this provider in the 60th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$203,219
Medicare patients
981
Services billed
3,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine117$141,045
XiidraLifitegrast106$137,740
LumiganBimatoprost74$30,014
TyrvayaVarenicline Tartrate30$22,967
MieboPerfluorohexyloctane/Pf27$22,826
Prednisolone Acetate300$9,035
Tobramycin-DexamethasoneTobramycin/Dexamethasone121$5,539
CombiganBrimonidine Tartrate/Timolol16$4,283
Latanoprost404$4,225
Travoprost15$3,506
Loteprednol Etabonate26$2,976
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat184$2,385
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol25$2,267
Doxycycline Hyclate73$1,782
Ketorolac Tromethamine77$1,194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$127$160,566133 claims
Oyster Point Pharma, Inc.Tyrvaya$23$22,96730 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$251$2,97626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →